Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

Xiao Du Guo, Nancy Harold, M. Wasif Saif, Barbara Schuler, Eva Szabo, J. Michael Hamilton, Brian P. Monahan, Mary G. Quinn, Janet Cliatt, Diana Nguyen, Frank Grollman, Rebecca R. Thomas, Elizabeth A. McQuigan, Richard Wilson, Chis H. Takimoto, Jean L Grem

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received a single 24-h i.v. infusion of 5-FU 2300 mg/m2 to provide a pharmacokinetic reference. After 2 weeks, patients received oral EU 20 mg plus LV 30 mg on days 1-3 with a single dose of 5-FU 15-29 mg/m2 on day 2, or LV 30 mg on days 1-2 with a single dose of EU at least 1 h prior to 5-FU 29 mg/m2 on day 2 weekly for 3 of 4 weeks. Results: Diarrhea was the most common dose-limiting toxicity. The recommended dose of 5-FU is 29 mg/m2 per day. EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to > 5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%. With EU, plasma fluoro-β-alanine was not detected while urinary excretion was reduced to < 1% of that seen with i.v. 5-FU alone. Marked increases in both plasma and urinary uracil were seen. Thymidylate synthase ternary complex formation was demonstrated in bone marrow mononuclear cells isolated 24 h after the first oral 5-FU dose; the average was 66.5% bound. Conclusions: Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume52
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Pharmacodynamics
Pharmacokinetics
Leucovorin
Fluorouracil
Appointments and Schedules
Thymidylate Synthase
Plasmas
Toxicity
eniluracil
Dihydrouracil Dehydrogenase (NADP)
Uracil
Bone Marrow Cells
Alanine
Half-Life
Diarrhea
Bone

Keywords

  • Dihydropyrimidine dehydrogenase
  • Eniluracil
  • Fluorouracil
  • Pharmacokinetics
  • Thymidylate synthase

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. / Guo, Xiao Du; Harold, Nancy; Wasif Saif, M.; Schuler, Barbara; Szabo, Eva; Hamilton, J. Michael; Monahan, Brian P.; Quinn, Mary G.; Cliatt, Janet; Nguyen, Diana; Grollman, Frank; Thomas, Rebecca R.; McQuigan, Elizabeth A.; Wilson, Richard; Takimoto, Chis H.; Grem, Jean L.

In: Cancer Chemotherapy and Pharmacology, Vol. 52, No. 1, 01.07.2003, p. 79-85.

Research output: Contribution to journalArticle

Guo, XD, Harold, N, Wasif Saif, M, Schuler, B, Szabo, E, Hamilton, JM, Monahan, BP, Quinn, MG, Cliatt, J, Nguyen, D, Grollman, F, Thomas, RR, McQuigan, EA, Wilson, R, Takimoto, CH & Grem, JL 2003, 'Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule', Cancer Chemotherapy and Pharmacology, vol. 52, no. 1, pp. 79-85. https://doi.org/10.1007/s00280-003-0613-0
Guo, Xiao Du ; Harold, Nancy ; Wasif Saif, M. ; Schuler, Barbara ; Szabo, Eva ; Hamilton, J. Michael ; Monahan, Brian P. ; Quinn, Mary G. ; Cliatt, Janet ; Nguyen, Diana ; Grollman, Frank ; Thomas, Rebecca R. ; McQuigan, Elizabeth A. ; Wilson, Richard ; Takimoto, Chis H. ; Grem, Jean L. / Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 52, No. 1. pp. 79-85.
@article{a65f16e2a83d4447b9393769c6fa4ab4,
title = "Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule",
abstract = "Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received a single 24-h i.v. infusion of 5-FU 2300 mg/m2 to provide a pharmacokinetic reference. After 2 weeks, patients received oral EU 20 mg plus LV 30 mg on days 1-3 with a single dose of 5-FU 15-29 mg/m2 on day 2, or LV 30 mg on days 1-2 with a single dose of EU at least 1 h prior to 5-FU 29 mg/m2 on day 2 weekly for 3 of 4 weeks. Results: Diarrhea was the most common dose-limiting toxicity. The recommended dose of 5-FU is 29 mg/m2 per day. EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to > 5 h, and increased the percentage of 5-FU excreted in the urine from 2{\%} to 64-66{\%}. With EU, plasma fluoro-β-alanine was not detected while urinary excretion was reduced to < 1{\%} of that seen with i.v. 5-FU alone. Marked increases in both plasma and urinary uracil were seen. Thymidylate synthase ternary complex formation was demonstrated in bone marrow mononuclear cells isolated 24 h after the first oral 5-FU dose; the average was 66.5{\%} bound. Conclusions: Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase.",
keywords = "Dihydropyrimidine dehydrogenase, Eniluracil, Fluorouracil, Pharmacokinetics, Thymidylate synthase",
author = "Guo, {Xiao Du} and Nancy Harold and {Wasif Saif}, M. and Barbara Schuler and Eva Szabo and Hamilton, {J. Michael} and Monahan, {Brian P.} and Quinn, {Mary G.} and Janet Cliatt and Diana Nguyen and Frank Grollman and Thomas, {Rebecca R.} and McQuigan, {Elizabeth A.} and Richard Wilson and Takimoto, {Chis H.} and Grem, {Jean L}",
year = "2003",
month = "7",
day = "1",
doi = "10.1007/s00280-003-0613-0",
language = "English (US)",
volume = "52",
pages = "79--85",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

AU - Guo, Xiao Du

AU - Harold, Nancy

AU - Wasif Saif, M.

AU - Schuler, Barbara

AU - Szabo, Eva

AU - Hamilton, J. Michael

AU - Monahan, Brian P.

AU - Quinn, Mary G.

AU - Cliatt, Janet

AU - Nguyen, Diana

AU - Grollman, Frank

AU - Thomas, Rebecca R.

AU - McQuigan, Elizabeth A.

AU - Wilson, Richard

AU - Takimoto, Chis H.

AU - Grem, Jean L

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received a single 24-h i.v. infusion of 5-FU 2300 mg/m2 to provide a pharmacokinetic reference. After 2 weeks, patients received oral EU 20 mg plus LV 30 mg on days 1-3 with a single dose of 5-FU 15-29 mg/m2 on day 2, or LV 30 mg on days 1-2 with a single dose of EU at least 1 h prior to 5-FU 29 mg/m2 on day 2 weekly for 3 of 4 weeks. Results: Diarrhea was the most common dose-limiting toxicity. The recommended dose of 5-FU is 29 mg/m2 per day. EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to > 5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%. With EU, plasma fluoro-β-alanine was not detected while urinary excretion was reduced to < 1% of that seen with i.v. 5-FU alone. Marked increases in both plasma and urinary uracil were seen. Thymidylate synthase ternary complex formation was demonstrated in bone marrow mononuclear cells isolated 24 h after the first oral 5-FU dose; the average was 66.5% bound. Conclusions: Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase.

AB - Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received a single 24-h i.v. infusion of 5-FU 2300 mg/m2 to provide a pharmacokinetic reference. After 2 weeks, patients received oral EU 20 mg plus LV 30 mg on days 1-3 with a single dose of 5-FU 15-29 mg/m2 on day 2, or LV 30 mg on days 1-2 with a single dose of EU at least 1 h prior to 5-FU 29 mg/m2 on day 2 weekly for 3 of 4 weeks. Results: Diarrhea was the most common dose-limiting toxicity. The recommended dose of 5-FU is 29 mg/m2 per day. EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to > 5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%. With EU, plasma fluoro-β-alanine was not detected while urinary excretion was reduced to < 1% of that seen with i.v. 5-FU alone. Marked increases in both plasma and urinary uracil were seen. Thymidylate synthase ternary complex formation was demonstrated in bone marrow mononuclear cells isolated 24 h after the first oral 5-FU dose; the average was 66.5% bound. Conclusions: Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase.

KW - Dihydropyrimidine dehydrogenase

KW - Eniluracil

KW - Fluorouracil

KW - Pharmacokinetics

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=0042671111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042671111&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0613-0

DO - 10.1007/s00280-003-0613-0

M3 - Article

VL - 52

SP - 79

EP - 85

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -